Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:phenylpyridine
go back to main search page
Accession:CHEBI:38193 term browser browse the term
Synonyms:related_synonym: phenylpyridines



show annotations for term's descendants           Sort by:
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ABCG2 protein CTD PMID:19732497 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Acaa2 acetyl-CoA acyltransferase 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ACAA2 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA]
CTD PMID:20230807 NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
JBrowse link
G Ache acetylcholinesterase decreases expression
decreases activity
multiple interactions
affects response to substance
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACHE mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of ACHE protein
ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein]
ACHE protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
CTD PMID:15329391 PMID:23201480 PMID:30529163 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACP5 mRNA CTD PMID:30529163 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 multiple interactions
increases expression
ISO 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACSL4 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACSL4 protein] CTD PMID:36435477 NCBI chr  X:105,942,794...106,006,573
Ensembl chr  X:105,942,799...106,006,427
JBrowse link
G Actr1a actin related protein 1A increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]
CTD PMID:20230807 NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
JBrowse link
G Adcy7 adenylate cyclase 7 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADCY7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ADCY7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]
CTD PMID:20230807 NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
JBrowse link
G Adgrl1 adhesion G protein-coupled receptor L1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]
CTD PMID:20230807 NCBI chr19:24,202,405...24,244,137
Ensembl chr19:24,204,360...24,244,139
JBrowse link
G Adnp activity-dependent neuroprotector homeobox decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADNP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA]
CTD PMID:20230807 NCBI chr 3:156,886,921...156,921,500
Ensembl chr 3:156,891,381...156,917,312
JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions
increases expression
ISO amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein] CTD PMID:28185818 PMID:37741537 PMID:38016618 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of AKR1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of AKR1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]
CTD PMID:20230807 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein
AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]
CTD PMID:21856379 PMID:22891246 PMID:28978077 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]
CTD PMID:20230807 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
JBrowse link
G Apex1 apurinic/apyrimidinic endodeoxyribonuclease 1 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA] CTD PMID:20230807 NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
JBrowse link
G Api5 apoptosis inhibitor 5 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of API5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA]
CTD PMID:20230807 NCBI chr 3:80,378,096...80,403,259
Ensembl chr 3:80,378,096...80,403,264
JBrowse link
G Arf1 ADP-ribosylation factor 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ARF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]
CTD PMID:20230807 NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
JBrowse link
G Arf3 ADP-ribosylation factor 3 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA]
CTD PMID:20230807 NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
JBrowse link
G Arpp21 cAMP regulated phosphoprotein 21 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ARPP21 mRNA CTD PMID:29627306 NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
JBrowse link
G Aspm assembly factor for spindle microtubules decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ASPM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA]
CTD PMID:20230807 NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta multiple interactions
increases expression
ISO Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATP5F1B protein] CTD PMID:23562983 NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
JBrowse link
G Atp6v0a4 ATPase H+ transporting V0 subunit a4 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP6V0A4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA]
CTD PMID:20230807 NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
JBrowse link
G Atp6v0c ATPase H+ transporting V0 subunit C decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V0C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA]
CTD PMID:20230807 NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
JBrowse link
G Atp6v1b2 ATPase H+ transporting V1 subunit B2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V1B2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA]
CTD PMID:20230807 NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
JBrowse link
G Atp6v1e2 ATPase H+ transporting V1 subunit E2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1E2 mRNA CTD PMID:28801915 NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626
JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP9A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA]
CTD PMID:20230807 NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
JBrowse link
G Atrn attractin increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]
CTD PMID:20230807 NCBI chr 3:118,110,320...118,244,326
Ensembl chr 3:118,110,229...118,244,322
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions
increases expression
ISO 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAD protein] CTD PMID:23911879 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bap1 Brca1 associated protein 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BAP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA]
CTD PMID:20230807 NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein] CTD PMID:24095822 PMID:24768735 PMID:24995576 PMID:25968939 PMID:28185818 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein] CTD PMID:23911879 PMID:24095822 PMID:24768735 PMID:24995576 PMID:25968939 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl2l10 Bcl2-like 10 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2L10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA]
CTD PMID:20230807 NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions
increases expression
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein
geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BDNF mRNA
CTD PMID:15329391 PMID:23747572 PMID:23943375 PMID:24991814 PMID:29030221 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BGLAP mRNA CTD PMID:30529163 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]
CTD PMID:20230807 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G C1r complement C1r increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]
CTD PMID:20230807 NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
JBrowse link
G C1s complement C1s multiple interactions
increases expression
ISO Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1S mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1S mRNA] CTD PMID:20230807 NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
JBrowse link
G Calm1 calmodulin 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CALM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CALM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]
CTD PMID:20230807 NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
JBrowse link
G Capzb capping actin protein of muscle Z-line subunit beta decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAPZB mRNA CTD PMID:15329391 NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409
JBrowse link
G Card10 caspase recruitment domain family, member 10 multiple interactions ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CARD10 mRNA CTD PMID:25406165 NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
JBrowse link
G Casp1 caspase 1 multiple interactions
increases expression
ISO 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein
CTD PMID:15329391 PMID:25406165 PMID:38016618 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Casp12 caspase 12 increases expression
increases cleavage
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA]
CTD PMID:20230807 PMID:24140863 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases cleavage
increases activity
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein]; 6,7-dihydroxyflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of CASP3 protein]; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein
CTD PMID:15329391 PMID:20133810 PMID:23201480 PMID:23911879 PMID:23933227 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases expression
increases cleavage
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein]; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]
CTD PMID:20230807 PMID:23201480 PMID:23911879 PMID:24768735 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions
decreases activity
decreases expression
ISO
EXP
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]
CTD PMID:24768735 PMID:25053526 PMID:33368846 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cbx5 chromobox 5 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CBX5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CBX5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA] CTD PMID:20230807 NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]
CTD PMID:22746536 PMID:25406165 PMID:27277809 PMID:30195017 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccnb1 cyclin B1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA]
CTD PMID:20230807 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd2 cyclin D2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCND2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA]
CTD PMID:20230807 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccnf cyclin F increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CCNF mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA]
CTD PMID:20230807 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
JBrowse link
G Ccnl2 cyclin L2 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA] CTD PMID:20230807 NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]
CTD PMID:30195017 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
JBrowse link
G Cd151 CD151 molecule (Raph blood group) decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD151 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA]
CTD PMID:20230807 NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
JBrowse link
G Cd44 CD44 molecule increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CD44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA]
CTD PMID:20230807 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
JBrowse link
G Cd68 Cd68 molecule multiple interactions
increases expression
ISO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA] CTD PMID:22746536 PMID:27277809 NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
JBrowse link
G Cd9 CD9 molecule multiple interactions
increases expression
ISO [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD9 mRNA] CTD PMID:20230807 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
JBrowse link
G Cdc42 cell division cycle 42 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDC42 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA]
CTD PMID:20230807 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
JBrowse link
G Cdh11 cadherin 11 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CDH11 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDH11 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA] CTD PMID:20230807 NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDK5R1 mRNA CTD PMID:15329391 NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
JBrowse link
G Cdk5r2 cyclin-dependent kinase 5 regulatory subunit 2 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDK5R2 mRNA CTD PMID:15329391 NCBI chr 9:76,416,251...76,417,719
Ensembl chr 9:76,416,062...76,418,344
JBrowse link
G Cdkn2d cyclin dependent kinase inhibitor 2D increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDKN2D mRNA CTD PMID:15329391 NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
JBrowse link
G Cetn3 centrin 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]
CTD PMID:20230807 NCBI chr 2:12,089,025...12,101,828
Ensembl chr 2:12,089,226...12,101,828
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CFLAR mRNA CTD PMID:15329391 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions
decreases expression
ISO Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein] CTD PMID:19594327 NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
JBrowse link
G Chrna6 cholinergic receptor nicotinic alpha 6 subunit decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA6 protein CTD PMID:19594327 NCBI chr16:64,697,741...64,704,441
Ensembl chr16:64,697,741...64,704,441
JBrowse link
G Cib1 calcium and integrin binding 1 increases expression
increases response to substance
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA
CIB1 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CIB1 mRNA; CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA]
CTD PMID:20230807 PMID:28939911 NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
JBrowse link
G Ckmt1 creatine kinase, mitochondrial 1 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CKMT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CKMT1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA] CTD PMID:20230807 NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758
JBrowse link
G Clca2 chloride channel accessory 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CLCA2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA]
CTD PMID:20230807 NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
JBrowse link
G Clstn1 calsyntenin 1 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA] CTD PMID:20230807 NCBI chr 5:160,031,235...160,094,585
Ensembl chr 5:160,031,308...160,094,583
JBrowse link
G Cnn2 calponin 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]
CTD PMID:20230807 NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
JBrowse link
G Cnr1 cannabinoid receptor 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein
AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein]
CTD PMID:28978077 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cnr2 cannabinoid receptor 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein
AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein]
CTD PMID:28978077 NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COL1A1 mRNA
CTD PMID:20230807 PMID:30529163 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col6a1 collagen type VI alpha 1 chain increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL6A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA]
CTD PMID:20230807 NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
JBrowse link
G Coq8a coenzyme Q8A multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COQ8A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COQ8A mRNA] CTD PMID:20230807 NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
JBrowse link
G Cox5a cytochrome c oxidase subunit 5A decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]
CTD PMID:23562983 NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
JBrowse link
G Cox7a2l cytochrome c oxidase subunit 7A2 like decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7A2L mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of COX7A2L mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]
CTD PMID:20230807 NCBI chr 6:11,184,064...11,198,287
Ensembl chr 6:11,184,285...11,198,273
JBrowse link
G Cox7c cytochrome c oxidase subunit 7C decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]
CTD PMID:20230807 PMID:24768735 NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
JBrowse link
G Creb1 cAMP responsive element binding protein 1 increases phosphorylation ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of CREB1 protein CTD PMID:27566062 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Csf3 colony stimulating factor 3 multiple interactions ISO CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] CTD PMID:27044752 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
JBrowse link
G Cst3 cystatin C decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CST3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CST3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]
CTD PMID:20230807 NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
JBrowse link
G Ctsb cathepsin B increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]
CTD PMID:20230807 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Ctsl cathepsin L increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CTSL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]
CTD PMID:20230807 NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
JBrowse link
G Cyc1 cytochrome c-1 multiple interactions ISO [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein] CTD PMID:24768735 NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYP11A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA]
CTD PMID:20230807 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing
multiple interactions
decreases expression
ISO CYP2D6 protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein
CTD PMID:12464242 PMID:19594327 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DCXR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA]
CTD PMID:20230807 NCBI chr10:106,006,404...106,008,293 JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein
Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
CTD PMID:22940226 PMID:24140863 PMID:28082123 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dhfr dihydrofolate reductase decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DHFR protein CTD PMID:31187328 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Dlst dihydrolipoamide S-succinyltransferase increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein]
CTD PMID:23562983 NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
JBrowse link
G Dlx5 distal-less homeobox 5 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLX5 mRNA CTD PMID:29627306 NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
JBrowse link
G Dnaja1 DnaJ heat shock protein family (Hsp40) member A1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]
CTD PMID:20230807 NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of DNAJB9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJB9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]
CTD PMID:20230807 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
JBrowse link
G Dpp4 dipeptidylpeptidase 4 increases expression
multiple interactions
increases activity
ISO
EXP
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]
MPTP increases activity of Dpp4 protein in the frontal cortex and nucleus accumbens
CTD
RGD
PMID:20230807 PMID:17415460 RGD:1626457 NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
JBrowse link
G Dpysl2 dihydropyrimidinase-like 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein]
CTD PMID:23562983 NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
JBrowse link
G Ecm1 extracellular matrix protein 1 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ECM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ECM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA] CTD PMID:20230807 NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF1A1 mRNA] CTD PMID:20230807 NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
JBrowse link
G Eef2 eukaryotic translation elongation factor 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA]
CTD PMID:20230807 NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
JBrowse link
G Efna1 ephrin A1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA]
CTD PMID:20230807 NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Efnb3 ephrin B3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNB3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EFNB3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]
CTD PMID:20230807 NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471
JBrowse link
G Egr1 early growth response 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EGR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA]
CTD PMID:20230807 PMID:28801915 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Egr2 early growth response 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR2 mRNA CTD PMID:28801915 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A affects phosphorylation ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the phosphorylation of EIF2A protein CTD PMID:20382208 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 affects phosphorylation ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the phosphorylation of EIF2AK2 protein CTD PMID:20382208 NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
JBrowse link
G Eif2b4 eukaryotic translation initiation factor 2B subunit delta decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF2B4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA]
CTD PMID:20230807 NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA] CTD PMID:20230807 NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
JBrowse link
G Eif5 eukaryotic translation initiation factor 5 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EIF5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]
CTD PMID:20230807 NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
JBrowse link
G En1 engrailed homeobox 1 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] CTD PMID:21892157 NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943
JBrowse link
G En2 engrailed homeobox 2 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] CTD PMID:21892157 NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943
JBrowse link
G Eno1 enolase 1 decreases expression
multiple interactions
increases expression
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]
CTD PMID:20230807 PMID:23562983 NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
JBrowse link
G Eno2 enolase 2 increases expression
decreases expression
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO2 mRNA
CTD PMID:23562983 PMID:30236862 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Epas1 endothelial PAS domain protein 1 multiple interactions ISO [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EPAS1 mRNA CTD PMID:19679656 NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]
CTD PMID:20230807 PMID:24140863 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Erp44 endoplasmic reticulum protein 44 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERP44 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ERP44 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]
CTD PMID:20230807 NCBI chr 5:62,516,550...62,610,762
Ensembl chr 5:62,516,551...62,610,761
JBrowse link
G Etfa electron transfer flavoprotein subunit alpha decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ETFA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA]
CTD PMID:20230807 NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
JBrowse link
G Ezr ezrin multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EZR mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EZR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA] CTD PMID:20230807 NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of FADD mRNA CTD PMID:25406165 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
JBrowse link
G Faslg Fas ligand multiple interactions ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of FASL mRNA CTD PMID:25406165 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fbxl12 F-box and leucine-rich repeat protein 12 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of FBXL12 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FBXL12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA] CTD PMID:20230807 NCBI chr 8:19,175,864...19,183,373
Ensembl chr 8:19,160,352...19,183,607
JBrowse link
G Fgf2 fibroblast growth factor 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FGF2 mRNA CTD PMID:28801915 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fmc1 formation of mitochondrial complex V assembly factor 1 decreases response to substance
decreases expression
ISO FMC1 gene mutant form results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 protein
CTD PMID:29371327 NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140
JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein alternative form CTD PMID:27566062 NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
JBrowse link
G Fth1 ferritin heavy chain 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein
3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein]
CTD PMID:36435477 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FYN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FYN mRNA] CTD PMID:20230807 NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
JBrowse link
G Gab1 GRB2-associated binding protein 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA]
CTD PMID:20230807 NCBI chr19:27,131,262...27,239,236
Ensembl chr19:27,131,262...27,239,236
JBrowse link
G Gale UDP-galactose-4-epimerase increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GALE mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA]
CTD PMID:20230807 NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
JBrowse link
G Gap43 growth associated protein 43 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]
CTD PMID:23933227 NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]
CTD PMID:20230807 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
JBrowse link
G Gata6 GATA binding protein 6 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GATA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA]
CTD PMID:20230807 NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
JBrowse link
G Gch1 GTP cyclohydrolase 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCH1 protein CTD PMID:31187328 NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GCLC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA]
CTD PMID:20230807 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLM protein CTD PMID:31187328 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions
decreases expression
ISO [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein
geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]
CTD PMID:19647008 PMID:23747572 PMID:23943375 NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression
ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of GFAP protein; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GFAP protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GFAP protein]; Zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein] CTD PMID:16809432 PMID:19199078 PMID:23747572 PMID:24995576 PMID:25064079 More... NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Ghitm growth hormone inducible transmembrane protein decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GHITM mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GHITM mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]
CTD PMID:20230807 NCBI chr16:12,885,551...12,897,887
Ensembl chr16:12,885,553...12,897,879
JBrowse link
G Glg1 golgi glycoprotein 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GLG1 mRNA CTD PMID:15329391 NCBI chr19:39,124,892...39,224,178
Ensembl chr19:39,124,641...39,224,178
JBrowse link
G Gmfb glia maturation factor, beta increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]
CTD PMID:20230807 NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GNAI2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA]
CTD PMID:20230807 NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
JBrowse link
G Golt1b golgi transport 1B increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]
CTD PMID:20230807 NCBI chr 4:175,333,056...175,346,156
Ensembl chr 4:175,333,092...175,346,153
JBrowse link
G Gpr55 G protein-coupled receptor 55 multiple interactions ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of GPR55 protein CTD PMID:28807673 NCBI chr 9:86,584,906...86,640,601
Ensembl chr 9:86,590,885...86,640,613
JBrowse link
G Gprc5c G protein-coupled receptor, class C, group 5, member C increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPRC5C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA]
CTD PMID:20230807 NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO GPX1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form] CTD PMID:19857570 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA] CTD PMID:20230807 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein
3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein]
CTD PMID:36435477 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
JBrowse link
G Grid2 glutamate ionotropic receptor delta type subunit 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]
CTD PMID:20230807 NCBI chr 4:92,415,019...93,892,472
Ensembl chr 4:92,415,230...93,889,355
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 increases expression
multiple interactions
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein
[mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]
CTD PMID:23538867 PMID:28092019 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases phosphorylation
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]
CTD PMID:22891246 PMID:23911879 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Gspt2 G1 to S phase transition 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GSPT2 mRNA CTD PMID:28801915 NCBI chr  X:59,587,237...59,589,758
Ensembl chr  X:59,587,276...59,594,162
JBrowse link
G Gtf2i general transcription factor II I decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GTF2I mRNA CTD PMID:15329391 NCBI chr12:22,400,933...22,476,243
Ensembl chr12:22,401,431...22,476,243
JBrowse link
G Hba-a1 hemoglobin alpha, adult chain 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]
CTD PMID:20230807 NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
JBrowse link
G Hells helicase, lymphoid specific increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]
CTD PMID:20230807 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO
EXP
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A mRNA; [Clioquinol co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A protein
[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein; [salicylaldehyde isonicotinoyl hydrazone co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein
CTD PMID:10961998 PMID:19679656 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hint1 histidine triad nucleotide binding protein 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]
CTD PMID:20230807 NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
JBrowse link
G Hipk1 homeodomain interacting protein kinase 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HIPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA]
CTD PMID:20230807 NCBI chr 2:191,248,817...191,299,787
Ensembl chr 2:191,248,817...191,298,902
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases expression
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 mRNA; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 protein; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein] CTD PMID:19679656 PMID:23933227 PMID:33368846 PMID:38016618 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hnrnpc heterogeneous nuclear ribonucleoprotein C decreases expression
multiple interactions
increases expression
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HNRNPC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HNRNPC mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HNRNPC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA]
CTD PMID:20230807 NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
JBrowse link
G Hras HRas proto-oncogene, GTPase decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]
CTD PMID:20230807 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]
CTD PMID:20230807 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
ISO TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]
Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]
CTD PMID:24140863 PMID:28082123 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Hspe1 heat shock protein family E (Hsp10) member 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA
Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]
CTD PMID:20230807 NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]
CTD PMID:30195017 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha multiple interactions
increases expression
ISO Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein] CTD PMID:23562983 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions
decreases expression
ISO IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IGF1 protein] CTD PMID:31351185 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Il17a interleukin 17A increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL17A protein
IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IGF1 protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
CTD PMID:31351185 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
JBrowse link
G Il1a interleukin 1 alpha decreases expression
multiple interactions
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA
CTD PMID:22940226 PMID:25406165 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP
ISO
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]
CTD PMID:12626429 PMID:22940226 PMID:24991814 PMID:24995576 PMID:25053526 More... NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]
CTD PMID:30195017 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]
CTD PMID:30195017 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il4r interleukin 4 receptor increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IL4RA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of IL4RA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]
CTD PMID:20230807 NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
JBrowse link
G Il6 interleukin 6 decreases response to substance
multiple interactions
decreases expression
increases expression
ISO
EXP
IL6 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]
CTD PMID:15804595 PMID:22940226 PMID:24995576 PMID:30195017 PMID:32968928 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]
CTD PMID:20230807 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521
JBrowse link
G Irx3 iroquois homeobox 3 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA] CTD PMID:20230807 NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317
JBrowse link
G Itm2b integral membrane protein 2B decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]
CTD PMID:20230807 NCBI chr15:48,545,998...48,568,904
Ensembl chr15:48,546,001...48,568,917
JBrowse link
G Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA]
CTD PMID:20230807 NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
JBrowse link
G Kat6b lysine acetyltransferase 6B multiple interactions
decreases expression
ISO [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KAT6B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KAT6B mRNA] CTD PMID:20230807 NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
JBrowse link
G Kcnj6 potassium inwardly-rectifying channel, subfamily J, member 6 affects response to substance ISO KCNJ6 affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CTD PMID:8172626 NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions
increases expression
decreases expression
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein] CTD PMID:33368846 PMID:38016618 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Kif1a kinesin family member 1A decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF1A mRNA CTD PMID:15329391 NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
JBrowse link
G Kif1b kinesin family member 1B decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF1B mRNA CTD PMID:15329391 NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
JBrowse link
G Kif3b kinesin family member 3B decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KIF3B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KIF3B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]
CTD PMID:20230807 NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963
JBrowse link
G Kif5a kinesin family member 5A decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF5A mRNA CTD PMID:15329391 NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
JBrowse link
G Kifc2 kinesin family member C2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIFC2 mRNA CTD PMID:15329391 NCBI chr 7:108,380,634...108,388,364
Ensembl chr 7:108,376,011...108,388,484
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions
increases expression
ISO TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KIT protein] CTD PMID:30195017 NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
JBrowse link
G Klf4 KLF transcription factor 4 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]
CTD PMID:20230807 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Kpna4 karyopherin subunit alpha 4 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KPNA4 protein CTD PMID:34427876 NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions
decreases expression
ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein] CTD PMID:33359019 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
JBrowse link
G Lpar4 lysophosphatidic acid receptor 4 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]
CTD PMID:20230807 NCBI chr  X:72,033,486...72,046,978
Ensembl chr  X:72,033,486...72,046,977
JBrowse link
G Lrrc10b leucine rich repeat containing 10B increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of LRRC10B mRNA CTD PMID:29627306 NCBI chr 1:207,096,471...207,097,699
Ensembl chr 1:207,022,919...207,098,045
JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of LRRK2 protein
HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of LRRK2 protein]
CTD PMID:32968928 NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
JBrowse link
G Maoa monoamine oxidase A increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAOA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAOA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]
CTD PMID:20230807 NCBI chr  X:6,032,172...6,098,308
Ensembl chr  X:6,030,795...6,099,593
JBrowse link
G Maob monoamine oxidase B multiple interactions
increases expression
increases activity
increases metabolic processing
increases oxidation
ISO [MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 1-Methyl-4-phenylpyridinium; [MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOB protein]; Zonisamide inhibits the reaction [[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of MAOB protein
5-nitroindazole inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; 9-mono-N'-methylnorharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Methylene Blue inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Vitamin K 3 inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
CTD PMID:19948168 PMID:21554916 PMID:23665943 PMID:24103762 PMID:30195017 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003
JBrowse link
G Map2 microtubule-associated protein 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MAP2 mRNA CTD PMID:15329391 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Map2k7 mitogen activated protein kinase kinase 7 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAP2K7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP2K7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA] CTD PMID:20230807 NCBI chr12:2,591,312...2,600,534
Ensembl chr12:2,591,219...2,604,222
JBrowse link
G Map3k12 mitogen activated protein kinase kinase kinase 12 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP3K12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA]
CTD PMID:20230807 NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases phosphorylation
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein
CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein]
CTD PMID:28939911 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases expression
decreases phosphorylation
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein
U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA]
CTD PMID:19857570 PMID:20230807 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein
U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein]
CTD PMID:19857570 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapt microtubule-associated protein tau increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPT mRNA CTD PMID:15329391 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
G Mark2 microtubule affinity regulating kinase 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MARK2 mRNA CTD PMID:15329391 NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652
JBrowse link
G Mc2r melanocortin 2 receptor decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MC2R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA]
CTD PMID:20230807 NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
JBrowse link
G Me1 malic enzyme 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ME1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA]
CTD PMID:20230807 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
JBrowse link
G Miat myocardial infarction associated transcript increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIAT mRNA CTD PMID:34967706 NCBI chr12:44,414,620...44,429,852 JBrowse link
G Mir138-1 microRNA 138-1 multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR138-1 mRNA] CTD PMID:29071302 NCBI chr 8:122,300,966...122,301,064
Ensembl chr 8:122,300,966...122,301,064
JBrowse link
G Mir142 microRNA 142 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR142 mRNA CTD PMID:34427876 NCBI chr10:72,557,864...72,557,950
Ensembl chr10:72,557,857...72,557,967
JBrowse link
G Mir153 microRNA 153 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR153 mRNA CTD PMID:31907031 NCBI chr 6:138,163,595...138,163,681
Ensembl chr 6:138,163,595...138,163,681
JBrowse link
G Mir15b microRNA 15b decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR15B mRNA CTD PMID:29217406 NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297
JBrowse link
G Mir210 microRNA 210 multiple interactions
increases expression
ISO MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR210 mRNA
CTD PMID:29030221 NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454
JBrowse link
G Mir221 microRNA 221 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR221 mRNA CTD PMID:34967706 NCBI chr  X:3,429,465...3,429,573
Ensembl chr  X:3,429,465...3,429,573
JBrowse link
G Mir330 microRNA 330 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR330 mRNA CTD PMID:29071302 NCBI chr 1:78,833,178...78,833,274
Ensembl chr 1:78,833,178...78,833,274
JBrowse link
G Mir503 microRNA 503 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MIR503 mRNA CTD PMID:29071302 NCBI chr  X:132,806,303...132,806,373
Ensembl chr  X:132,806,303...132,806,373
JBrowse link
G Mmp7 matrix metallopeptidase 7 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]
CTD PMID:20230807 NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
JBrowse link
G Mrpl10 mitochondrial ribosomal protein L10 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MRPL10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA]
CTD PMID:20230807 NCBI chr10:82,026,031...82,034,451
Ensembl chr10:82,026,031...82,034,443
JBrowse link
G Mrpl20 mitochondrial ribosomal protein L20 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]
CTD PMID:20230807 NCBI chr 5:166,408,962...166,413,492
Ensembl chr 5:166,408,962...166,413,492
JBrowse link
G mrpl9 mitochondrial ribosomal protein L9 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]
CTD PMID:20230807 NCBI chr 2:182,082,012...182,086,758
Ensembl chr 2:182,076,369...182,087,095
JBrowse link
G Mt2A metallothionein 2A increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]
CTD PMID:20230807 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
JBrowse link
G Mt3 metallothionein 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]
CTD PMID:23933227 NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
JBrowse link
G Mta1 metastasis associated 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein
CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]
CTD PMID:27044752 NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
JBrowse link
G Mtch1 mitochondrial carrier 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTCH1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MTCH1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]
CTD PMID:20230807 NCBI chr20:7,389,942...7,413,426
Ensembl chr20:7,389,949...7,413,426
JBrowse link
G Mtf2 metal response element binding transcription factor 2 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA] CTD PMID:20230807 NCBI chr14:1,639,256...1,683,513
Ensembl chr14:1,640,746...1,683,524
JBrowse link
G Mtor mechanistic target of rapamycin kinase affects phosphorylation ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the phosphorylation of MTOR protein CTD PMID:20382208 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Mup18 major urinary protein 18 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MUP18 mRNA CTD PMID:29627306 NCBI chr 5:74,986,813...74,990,071
Ensembl chr 5:74,842,319...75,061,474
JBrowse link
G Ncam1 neural cell adhesion molecule 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]
CTD PMID:23933227 NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
JBrowse link
G Ndufb5 NADH:ubiquinone oxidoreductase subunit B5 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NDUFB5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFB5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]
CTD PMID:20230807 NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 multiple interactions ISO NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] CTD PMID:21892157 NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFS4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA]
CTD PMID:20230807 NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases response to substance
multiple interactions
decreases expression
ISO NFE2L2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of MIR380 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR138-1 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR674 mRNA]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein
CTD PMID:22746536 PMID:24991814 PMID:29071302 PMID:31187328 PMID:33368846 More... NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of and results in increased phosphorylation of NFKBIA protein; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of and results in increased phosphorylation of NFKBIA protein] CTD PMID:37741537 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Ngb neuroglobin decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NGB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA]
CTD PMID:20230807 NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 mRNA]
CTD PMID:32968928 PMID:38016618 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NOS1 protein
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose]
CTD PMID:10318960 PMID:17555550 PMID:31187328 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
JBrowse link
G Nos2 nitric oxide synthase 2 increases activity
increases expression
multiple interactions
ISO
EXP
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein
[Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]
CTD PMID:12626429 PMID:22940226 PMID:23933227 PMID:24995576 PMID:28185818 More... NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Npl N-acetylneuraminate pyruvate lyase multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA] CTD PMID:20230807 NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372
JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 multiple interactions ISO 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein CTD PMID:25406165 NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
JBrowse link
G Nrf1 nuclear respiratory factor 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NRF1 protein CTD PMID:21856379 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Nsf N-ethylmaleimide sensitive factor, vesicle fusing ATPase increases expression
decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NSF mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NSF mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NSF mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]
CTD PMID:15329391 PMID:20230807 NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]
CTD PMID:20230807 NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
JBrowse link
G Ocln occludin multiple interactions
decreases expression
ISO [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of OCLN protein
CTD PMID:25064079 PMID:31351185 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
JBrowse link
G P3h3 prolyl 3-hydroxylase 3 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of P3H3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of P3H3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA] CTD PMID:20230807 NCBI chr 4:157,646,242...157,662,035
Ensembl chr 4:157,646,243...157,662,035
JBrowse link
G Pak2 p21 (RAC1) activated kinase 2 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA] CTD PMID:20230807 NCBI chr11:68,707,940...68,768,816
Ensembl chr11:68,707,969...68,768,816
JBrowse link
G Park7 Parkinsonism associated deglycase decreases response to substance
multiple interactions
increases expression
ISO PARK7 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PARK7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PARK7 mRNA]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
CTD PMID:15784737 PMID:20230807 PMID:22511790 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases response to substance
ISO [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Homovanillic Acid CTD PMID:10318960 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdcd6ip programmed cell death 6 interacting protein decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDCD6IP mRNA CTD PMID:15329391 NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773
JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PDIA6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PDIA6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]
CTD PMID:20230807 NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
increases expression
ISO TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PECAM1 protein] CTD PMID:30195017 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
JBrowse link
G Pfdn1 prefoldin subunit 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]
CTD PMID:20230807 NCBI chr18:28,014,145...28,067,148
Ensembl chr18:28,014,145...28,067,064
JBrowse link
G Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PFKFB3 mRNA CTD PMID:29627306 NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
JBrowse link
G Phb1 prohibitin 1 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA] CTD PMID:20230807 NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
JBrowse link
G Phtf1 putative homeodomain transcription factor 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PHTF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHTF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]
CTD PMID:20230807 NCBI chr 2:191,470,849...191,537,399
Ensembl chr 2:191,473,130...191,512,078
JBrowse link
G Pias1 protein inhibitor of activated STAT, 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PIAS1 mRNA CTD PMID:28801915 NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
JBrowse link
G Pidd1 p53-induced death domain protein 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]
CTD PMID:20230807 NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
JBrowse link
G Pigc phosphatidylinositol glycan anchor biosynthesis, class C increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]
CTD PMID:20230807 NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211
JBrowse link
G Pin1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PIN1 mRNA; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]
CTD PMID:20230807 PMID:23754278 NCBI chr 8:19,189,408...19,200,785
Ensembl chr 8:19,189,373...19,200,785
JBrowse link
G Pink1 PTEN induced kinase 1 affects response to substance
decreases expression
multiple interactions
ISO PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein
AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
CTD PMID:22511790 PMID:28978077 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
JBrowse link
G Pip5k1c phosphatidylinositol-4-phosphate 5-kinase type 1 gamma increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]
CTD PMID:20230807 NCBI chr 7:8,397,406...8,426,030
Ensembl chr 7:8,397,406...8,425,988
JBrowse link
G Plaa phospholipase A2, activating protein increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PLAA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA]
CTD PMID:20230807 NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282
JBrowse link
G Pnoc prepronociceptin affects response to substance ISO PNOC affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PNOC protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CTD PMID:16237164 PMID:26687234 NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867
JBrowse link
G Pnpla8 patatin-like phospholipase domain containing 8 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]
CTD PMID:20230807 NCBI chr 6:61,329,810...61,391,736
Ensembl chr 6:61,329,810...61,391,734
JBrowse link
G Pou4f2 POU class 4 homeobox 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of POU4F2 mRNA CTD PMID:29627306 NCBI chr19:29,486,686...29,490,327
Ensembl chr19:29,486,686...29,490,327
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA alternative form CTD PMID:30236862 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Ppm1b protein phosphatase, Mg2+/Mn2+ dependent, 1B decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPM1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PPM1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]
CTD PMID:20230807 NCBI chr 6:9,646,695...9,707,471
Ensembl chr 6:9,655,765...9,707,974
JBrowse link
G Ppp2r3c protein phosphatase 2, regulatory subunit B'', gamma increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]
CTD PMID:20230807 NCBI chr 6:72,647,025...72,670,885
Ensembl chr 6:72,647,025...72,672,491
JBrowse link
G Prdx2 peroxiredoxin 2 multiple interactions
decreases expression
ISO Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein] CTD PMID:23562983 NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
JBrowse link
G Prdx3 peroxiredoxin 3 increases expression
decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRDX3 mRNA; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]
CTD PMID:20230807 PMID:23562983 NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
JBrowse link
G Prep prolyl endopeptidase multiple interactions EXP MPTP increases activity of Prep protein in the frontal cortex and striatum; MPTP decreases activity of Prep protein in the hypothalamus RGD PMID:17415460 RGD:1626457 NCBI chr20:48,556,211...48,653,165
Ensembl chr20:48,556,280...48,654,466
JBrowse link
G Prkab1 protein kinase AMP-activated non-catalytic subunit beta 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRKAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA]
CTD PMID:20230807 NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions
decreases response to substance
decreases expression
increases expression
ISO PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH]
AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
PRKN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN protein
CTD PMID:22342763 PMID:22511790 PMID:23643664 PMID:25447324 PMID:27566062 More... NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
JBrowse link
G Psmc2 proteasome 26S subunit, ATPase 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA]
CTD PMID:20230807 NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
JBrowse link
G Psmc5 proteasome 26S subunit, ATPase 5 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]
CTD PMID:20230807 NCBI chr10:91,187,763...91,193,697
Ensembl chr10:91,187,743...91,213,135
JBrowse link
G Psmg2 proteasome assembly chaperone 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMG2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA]
CTD PMID:20230807 NCBI chr18:61,208,669...61,227,671
Ensembl chr18:61,208,678...61,259,816
JBrowse link
G Pten phosphatase and tensin homolog increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTEN protein CTD PMID:31907031 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
EXP
ISO
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]
CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein
CTD PMID:22940226 PMID:24995576 PMID:37741537 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pura purine rich element binding protein A decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PURA mRNA CTD PMID:15329391 NCBI chr18:27,885,071...27,905,509
Ensembl chr18:27,884,556...27,905,513
JBrowse link
G Pycard PYD and CARD domain containing increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PYCARD mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA]
CTD PMID:20230807 PMID:32968928 PMID:38016618 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
JBrowse link
G Rab2a RAB2A, member RAS oncogene family multiple interactions
increases expression
ISO [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAB2 mRNA] CTD PMID:20230807 NCBI chr 5:21,676,017...21,740,035
Ensembl chr 5:21,676,129...21,739,899
JBrowse link
G Rab3a RAB3A, member RAS oncogene family multiple interactions ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB3A protein] CTD PMID:15099020 NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
JBrowse link
G Rab5a RAB5A, member RAS oncogene family multiple interactions ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB5A protein] CTD PMID:15099020 NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAB7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]
CTD PMID:20230807 NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
JBrowse link
G Rab8a RAB8A, member RAS oncogene family multiple interactions ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB8A protein] CTD PMID:15099020 NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
JBrowse link
G Rad1 RAD1 checkpoint DNA exonuclease increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]
CTD PMID:20230807 NCBI chr 2:59,461,597...59,469,707
Ensembl chr 2:59,461,607...59,469,689
JBrowse link
G Rad50 RAD50 double strand break repair protein multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAD50 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD50 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA] CTD PMID:20230807 NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
JBrowse link
G Rangap1 RAN GTPase activating protein 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RANGAP1 mRNA CTD PMID:15329391 NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438
JBrowse link
G Rasa1 RAS p21 protein activator 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RASA1 mRNA CTD PMID:15329391 NCBI chr 2:15,857,704...15,940,757
Ensembl chr 2:15,857,980...15,940,854
JBrowse link
G Rasa3 RAS p21 protein activator 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]
CTD PMID:20230807 NCBI chr16:75,855,360...75,969,349
Ensembl chr16:75,855,265...75,970,804
JBrowse link
G Rbbp4 RB binding protein 4, chromatin remodeling factor multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA] CTD PMID:20230807 NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284
JBrowse link
G Rbbp5 RB binding protein 5, histone lysine methyltransferase complex subunit increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]
CTD PMID:20230807 NCBI chr13:43,912,254...43,939,107
Ensembl chr13:43,912,254...43,939,107
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects localization
increases phosphorylation
multiple interactions
increases expression
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RELA protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]
CTD PMID:22940226 PMID:34808223 PMID:37741537 PMID:38016618 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Ret ret proto-oncogene decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RET protein CTD PMID:17555550 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
JBrowse link
G Rgs2 regulator of G-protein signaling 2 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RGS2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RGS2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]
CTD PMID:20230807 NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
JBrowse link
G Rpl26 ribosomal protein L26 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA] CTD PMID:20230807 NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966
JBrowse link
G Rpl5 ribosomal protein L5 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RPL5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]
CTD PMID:20230807 NCBI chr14:1,843,856...1,850,301
Ensembl chr14:1,843,770...1,850,290
JBrowse link
G Rspo3 R-spondin 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]
CTD PMID:20230807 NCBI chr 1:28,283,914...28,368,661
Ensembl chr 1:28,283,914...28,367,061
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RUNX2 mRNA CTD PMID:30529163 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Sap18 Sin3A associated protein 18 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SAP18 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA]
CTD PMID:20230807 NCBI chr15:31,943,228...31,947,534
Ensembl chr15:31,943,230...31,950,038
Ensembl chr10:31,943,230...31,950,038
JBrowse link
G Senp6 SUMO specific peptidase 6 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SENP6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SENP6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]
CTD PMID:20230807 NCBI chr 8:80,988,675...81,071,606
Ensembl chr 8:80,989,052...81,067,170
JBrowse link
G Septin5 septin 5 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SEPTIN5 protein CTD PMID:23562983 NCBI chr11:82,373,601...82,379,393
Ensembl chr11:82,369,754...82,379,393
JBrowse link
G Septin7 septin 7 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]
CTD PMID:20230807 NCBI chr 8:23,719,448...23,783,247
Ensembl chr 8:23,716,030...23,783,243
JBrowse link
G Sfpq splicing factor proline and glutamine rich multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA] CTD PMID:20230807 NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472
JBrowse link
G Sgo1 shugoshin 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SGO1 mRNA CTD PMID:29627306 NCBI chr 9:6,672,109...6,687,908
Ensembl chr 9:6,672,123...6,687,805
JBrowse link
G Sh3kbp1 SH3 domain-containing kinase-binding protein 1 affects expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of SH3KBP1 protein CTD PMID:18535749 NCBI chr  X:34,877,862...35,223,013
Ensembl chr  X:34,877,866...35,222,747
JBrowse link
G Sirt2 sirtuin 2 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SIRT2 protein CTD PMID:27235848 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions
affects response to substance
decreases expression
decreases activity
ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC18A2 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC18A2 protein]; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]
SLC18A2 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein
CTD PMID:16011487 PMID:19653878 PMID:23747572 PMID:23943375 PMID:27287315 More... NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
JBrowse link
G Slc1a1 solute carrier family 1 member 1 affects localization
multiple interactions
affects metabolic processing
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein
Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein]; Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the metabolism of SLC1A1 protein]
CTD PMID:18093171 NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases response to substance ISO SLC22A1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CTD PMID:25248837 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases response to substance ISO SLC22A2 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CTD PMID:25248837 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
G Slc26a3 solute carrier family 26 member 3 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC26A3 mRNA CTD PMID:15329391 NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein] CTD PMID:25064079 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
JBrowse link
G Slc30a10 solute carrier family 30, member 10 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC30A10 protein CTD PMID:28688763 NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103
JBrowse link
G Slc40a1 solute carrier family 40 member 1 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein
3,4-dihydroxybenzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein]
CTD PMID:19679656 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
JBrowse link
G Slc6a3 solute carrier family 6 member 3 multiple interactions
increases expression
decreases expression
decreases activity
ISO 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein
CTD PMID:15329391 PMID:16011487 PMID:16725203 PMID:19653878 PMID:20079141 More... NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
JBrowse link
G Smad1 SMAD family member 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]
CTD PMID:20230807 NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651
JBrowse link
G Smad3 SMAD family member 3 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMAD3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]
CTD PMID:20230807 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
JBrowse link
G Smpd3 sphingomyelin phosphodiesterase 3 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMPD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMPD3 mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]
CTD PMID:20230807 NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
JBrowse link
G Snca synuclein alpha multiple interactions
increases expression
affects response to substance
ISO
EXP
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein binds to SNCA protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB3A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB5A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB8A protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein
U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SNCA protein alternative form; GPX1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]
SNCA affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNCA protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
CTD PMID:12732244 PMID:15099020 PMID:16809432 PMID:19032594 PMID:19857570 More... NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
JBrowse link
G Sncaip synuclein, alpha interacting protein increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCAIP mRNA CTD PMID:15329391 NCBI chr18:46,205,846...46,343,932
Ensembl chr18:46,207,152...46,343,929
JBrowse link
G Sncg synuclein, gamma increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SNCG mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA]
CTD PMID:20230807 NCBI chr16:9,700,513...9,705,751
Ensembl chr16:9,700,514...9,705,368
JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOCS3 mRNA CTD PMID:28801915 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
JBrowse link
G Sod2 superoxide dismutase 2 increases expression
decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SOD2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein
[3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SOD2 protein; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]
CTD PMID:19679656 PMID:23562983 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox14 SRY-box transcription factor 14 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOX14 mRNA CTD PMID:29627306 NCBI chr 8:100,421,982...100,423,918
Ensembl chr 8:100,421,982...100,423,918
JBrowse link
G Sp1 Sp1 transcription factor increases expression
affects response to substance
multiple interactions
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA
SP1 affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein; [mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]
CTD PMID:23538867 PMID:25851821 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Sp3 Sp3 transcription factor increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP3 mRNA CTD PMID:29071302 NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342
JBrowse link
G Srf serum response factor increases phosphorylation ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of SRF protein CTD PMID:27566062 NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733
JBrowse link
G Srp9 signal recognition particle 9 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]
CTD PMID:20230807 NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
JBrowse link
G Srpk2 SRSF protein kinase 2 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRPK2 mRNA CTD PMID:15329391 NCBI chr 4:11,464,684...11,655,993
Ensembl chr 4:11,464,674...11,655,990
JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STAT3 mRNA CTD PMID:28801915 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Stip1 stress-induced phosphoprotein 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STIP1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STIP1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]
CTD PMID:20230807 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
JBrowse link
G Stmn1 stathmin 1 multiple interactions
decreases expression
ISO Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein] CTD PMID:23562983 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
JBrowse link
G Stx4 syntaxin 4 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STX4A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STX4A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]
CTD PMID:20230807 NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
JBrowse link
G Syn3 synapsin III decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYN3 mRNA CTD PMID:15329391 NCBI chr 7:16,216,055...17,808,790
Ensembl chr 7:17,376,372...17,808,790
JBrowse link
G Syngr1 synaptogyrin 1 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR1 mRNA CTD PMID:15329391 NCBI chr 7:111,635,911...111,659,341
Ensembl chr 7:111,635,918...111,659,341
JBrowse link
G Syngr2 synaptogyrin 2 multiple interactions
decreases expression
ISO [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SYNGR2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR2 mRNA] CTD PMID:20230807 NCBI chr10:103,029,903...103,034,473
Ensembl chr10:103,029,917...103,034,473
JBrowse link
G Syngr3 synaptogyrin 3 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR3 mRNA CTD PMID:15329391 NCBI chr10:13,710,553...13,715,309
Ensembl chr10:13,704,998...13,715,669
JBrowse link
G Syt10 synaptotagmin 10 decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYT10 mRNA CTD PMID:15329391 NCBI chr 7:120,857,698...120,920,863
Ensembl chr 7:120,862,972...120,920,863
JBrowse link
G Syt4 synaptotagmin 4 multiple interactions
decreases expression
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYT4 mRNA
CTD PMID:15329391 PMID:20230807 NCBI chr18:23,036,973...23,046,380
Ensembl chr18:23,038,378...23,046,332
JBrowse link
G Tal1 TAL bHLH transcription factor 1, erythroid differentiation factor decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TAL1 mRNA CTD PMID:29627306 NCBI chr 5:128,586,776...128,600,976
Ensembl chr 5:128,587,701...128,600,976
JBrowse link
G Tfam transcription factor A, mitochondrial decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TFAM protein CTD PMID:21856379 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
JBrowse link
G Tfrc transferrin receptor increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]
CTD PMID:20230807 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
ISO TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein]
[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib] results in increased secretion of TGFB1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein
CTD PMID:30195017 PMID:34967706 PMID:35007524 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFBR1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFBR1 protein CTD PMID:34967706 NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
JBrowse link
G Tgm2 transglutaminase 2 multiple interactions
increases expression
increases activity
ISO TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KIT protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PECAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGM2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of TGM2 protein
CTD PMID:30195017 NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
JBrowse link
G Th tyrosine hydroxylase multiple interactions
increases expression
decreases expression
ISO (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl)-3-azetidinol maleate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TH mRNA; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; [Zonisamide co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] affects the activity of TH protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein
CTD PMID:15329391 PMID:16402076 PMID:16725203 PMID:17555550 PMID:18535749 More... NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases expression
ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIGAR protein
CTD PMID:33359019 NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIMP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA]
CTD PMID:20230807 NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
JBrowse link
G Tirap TIR domain containing adaptor protein increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]
CTD PMID:20230807 NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions
decreases expression
ISO [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TJP1 protein
CTD PMID:25064079 PMID:31351185 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions
increases expression
ISO 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TLR4 protein] CTD PMID:25406165 PMID:34808223 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
EXP
ISO
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TNF mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]
CTD PMID:12626429 PMID:22746536 PMID:22940226 PMID:24991814 PMID:24995576 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B affects expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of TNFRSF11B mRNA CTD PMID:30529163 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfsf11 TNF superfamily member 11 affects expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of TNFSF11 mRNA CTD PMID:30529163 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tnk2 tyrosine kinase, non-receptor, 2 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TNK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TNK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA] CTD PMID:20230807 NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009
JBrowse link
G Tp53 tumor protein p53 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]
CTD PMID:23933227 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tp53inp1 tumor protein p53 inducible nuclear protein 1 multiple interactions ISO [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Nicotine] results in increased expression of TRP53INP1 mRNA CTD PMID:20230807 NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
JBrowse link
G Tph2 tryptophan hydroxylase 2 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA] CTD PMID:20230807 NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424
JBrowse link
G Tpp2 tripeptidyl peptidase 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]
CTD PMID:20230807 NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157
JBrowse link
G Traf2 Tnf receptor-associated factor 2 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein]
CTD PMID:24140863 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
JBrowse link
G Trpm2 transient receptor potential cation channel, subfamily M, member 2 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRPM2 protein CTD PMID:27957685 NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA] CTD PMID:20230807 NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
JBrowse link
G Ttr transthyretin increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TTR mRNA CTD PMID:29627306 NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
JBrowse link
G Tuba1a tubulin, alpha 1A increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein]
CTD PMID:23562983 NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
JBrowse link
G Txn1 thioredoxin 1 multiple interactions
decreases response to substance
decreases expression
ISO TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein]
Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein]
TXN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein
CTD PMID:24140863 PMID:28082123 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
JBrowse link
G Ubb ubiquitin B increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]
CTD PMID:20230807 NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
JBrowse link
G Ubc ubiquitin C decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]
CTD PMID:20230807 NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
JBrowse link
G Ube2d2 ubiquitin-conjugating enzyme E2D 2 multiple interactions
decreases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA] CTD PMID:20230807 NCBI chr18:27,364,325...27,406,322
Ensembl chr18:27,364,303...27,406,181
JBrowse link
G Uchl1 ubiquitin C-terminal hydrolase L1 multiple interactions
decreases response to substance
decreases expression
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]
UCHL1 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 protein
CTD PMID:15329391 PMID:20230807 PMID:22342763 PMID:23643664 NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
JBrowse link
G Uros uroporphyrinogen III synthase decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]
CTD PMID:20230807 NCBI chr 1:188,490,832...188,513,659
Ensembl chr 1:188,490,323...188,512,249
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein]
CTD PMID:30195017 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vip vasoactive intestinal peptide multiple interactions ISO VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein] CTD PMID:12626429 NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
JBrowse link
G Vps28 VPS28 subunit of ESCRT-I decreases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS28 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA]
CTD PMID:20230807 NCBI chr 7:108,341,989...108,345,837
Ensembl chr 7:108,341,989...108,345,837
JBrowse link
G Vps41 VPS41 subunit of HOPS complex increases expression
multiple interactions
ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of VPS41 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS41 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]
CTD PMID:20230807 NCBI chr17:46,063,132...46,227,533
Ensembl chr17:46,063,124...46,227,791
JBrowse link
G Wbp4 WW domain binding protein 4 multiple interactions
increases expression
ISO [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of WBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of WBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA] CTD PMID:20230807 NCBI chr15:54,862,700...54,890,668
Ensembl chr15:54,862,843...54,890,647
JBrowse link
G Xbp1 X-box binding protein 1 decreases response to substance ISO XBP1 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CTD PMID:19135031 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
G Ywhag tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma decreases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of YWHAG mRNA CTD PMID:15329391 NCBI chr12:20,744,500...20,772,828
Ensembl chr12:20,744,535...20,772,827
JBrowse link
G Zfp326 zinc finger protein 326 increases expression ISO 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ZFP326 mRNA CTD PMID:29627306 NCBI chr14:3,941,210...3,980,419
Ensembl chr14:3,941,958...3,980,384
JBrowse link
2-Acetoxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 increases response to substance
multiple interactions
ISO GSTA1 protein polymorphism results in increased susceptibility to 2-(acetoxyamino)-1-methyl-6-phenylimidazo(4,5-b)pyridine
GSTA1 protein affects the metabolism of and results in decreased activity of 2-(acetoxyamino)-1-methyl-6-phenylimidazo(4,5-b)pyridine
CTD PMID:8069858 PMID:11535243 PMID:15797627 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO GSTP1 protein affects the metabolism of and results in decreased activity of 2-(acetoxyamino)-1-methyl-6-phenylimidazo(4,5-b)pyridine CTD PMID:8069858 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fgf23 fibroblast growth factor 23 multiple interactions ISO 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl)-benzoic acid inhibits the reaction [FGF23 protein results in decreased uptake of Phosphates] CTD PMID:27432882 NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
JBrowse link
G Ins1 insulin 1 multiple interactions ISO 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl)-benzoic acid analog inhibits the reaction [INS1 protein results in increased phosphorylation of NDRG1 protein]; 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl)-benzoic acid deficiency inhibits the reaction [INS1 protein results in increased transport of Sodium] CTD PMID:20880397 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
JBrowse link
G Ndrg1 N-myc downstream regulated 1 multiple interactions
decreases phosphorylation
ISO 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl)-benzoic acid analog inhibits the reaction [INS1 protein results in increased phosphorylation of NDRG1 protein]
2-cyclopentyl-4-(5-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl)-benzoic acid analog results in decreased phosphorylation of NDRG1 protein
CTD PMID:20880397 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
JBrowse link
Fluridone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO fluridone inhibits the reaction [CCL2 protein results in increased secretion of Abscisic Acid]; fluridone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]
fluridone inhibits the reaction [Zymosan results in increased expression of CCL2 protein]
CTD PMID:24211328 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO fluridone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; fluridone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] CTD PMID:24211328 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19918
    chemical entity 19916
      atom 19916
        nonmetal atom 19852
          nitrogen atom 19013
            nitrogen molecular entity 19013
              organonitrogen compound 18856
                organonitrogen heterocyclic compound 18192
                  pyridines 11526
                    phenylpyridine 377
                      (+)-didymellamide B 0
                      (+)-ganoapplanatumine A 0
                      (+)-tersone A 0
                      (+)-tersone B 0
                      (+)-tersone C 0
                      (+)-tersone D 0
                      (+)-tersone E 0
                      (+/-)-didymellamide E 0
                      (-)-ganoapplanatumine A 0
                      (-)-tersone A 0
                      (-)-tersone B 0
                      (-)-tersone C 0
                      (-)-tersone D 0
                      (-)-tersone E 0
                      (10,11-Z)-syn-13-hydroxypretenellin B 0
                      (2R)-2-[(4R,5R)-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-2-yl]-1-propanol 0
                      (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(2-fluorophenyl)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3R,3aS,9bS)-1-(cyclopentanecarbonyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                      (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-7-(3-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-acetyl-N-[3-(dimethylamino)propyl]-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-1-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-N-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-1-ethyl-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-2-N-cyclobutyl-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                      (2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methyl-2-(piperidine-1-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(1,3-thiazol-2-yl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-1-methyl-6-oxo-N-[2-(1-piperidinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-2-(morpholine-4-carbonyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-2-(4-methylpiperazine-1-carbonyl)-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                      (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-[oxo(1-piperidinyl)methyl]-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-[4-(dimethylcarbamoyl)phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-N-(2-phenylethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N,1-diethyl-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-(4-oxanylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-7-[3-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-cyclobutyl-1-[2-(dimethylamino)acetyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-cyclobutyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2R,3R,3aS,9bS)-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                      (2R,3R,4S)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-1-azetidinecarboxamide 0
                      (2R,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (2R,3S)-2-[(dimethylamino)methyl]-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2R,3S,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-(4-pyridin-3-ylphenyl)azetidine-1-carboxamide 0
                      (2R,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (2S)-2-[(4S,5S)-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-2-yl]-1-propanol 0
                      (2S)-2-[[9-propan-2-yl-6-[[4-(2-pyridinyl)phenyl]methylamino]-2-purinyl]amino]-1-butanol 0
                      (2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3R,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-1-azetidinecarboxamide 0
                      (2S,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                      (2S,3S,3aR,9bR)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-(cyclopropanecarbonyl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                      (2S,3S,3aR,9bR)-1-[cyclopentyl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-acetyl-N-[3-(dimethylamino)propyl]-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-1-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-N-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-1-ethyl-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methyl-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-1-methyl-6-oxo-N-(2-piperidin-1-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-2-[4-morpholinyl(oxo)methyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                      (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                      (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-(piperidine-1-carbonyl)-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-N-(2-phenylethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N,1-diethyl-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-(4-oxanylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-7-[3-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-cyclobutyl-1-[2-(dimethylamino)acetyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-cyclobutyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                      (2S,3S,3aR,9bR)-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                      (2S,3S,3aR,9bR)-N2-cyclobutyl-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                      (2S,3S,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-(4-pyridin-3-ylphenyl)azetidine-1-carboxamide 0
                      (2S,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3-methoxyphenyl)methyl]-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-[(R)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-ethylsulfonyl-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                      (3R)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                      (3R)-4-(3-bromophenyl)-2-[(R)-tert-butylsulfinyl]-N-cyclohexyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                      (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3R)-N6-(2,3-dihydro-1H-inden-2-yl)-3-(2-hydroxyethyl)-N2-propan-2-yl-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2,6-dicarboxamide 0
                      (3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-3-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3-methoxyphenyl)methyl]-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-N-ethyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-[(S)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-ethylsulfonyl-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                      (3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                      (3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                      (3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-4-(3-bromophenyl)-2-[(S)-tert-butylsulfinyl]-N-cyclohexyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                      (3S)-4-[3-(1-cyclohexenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-2-methylsulfonyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                      (3S)-N6-(2,3-dihydro-1H-inden-2-yl)-3-(2-hydroxyethyl)-N2-propan-2-yl-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2,6-dicarboxamide 0
                      (4-Pyrid-4-ylphenyl)methanol 0
                      (6R,7R,8R)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7R,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6R,7R,8S)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7R,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6R,7S,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6R,7S,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6R,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6S,7R,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6S,7R,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7S,8R)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7S,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6S,7S,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6S,7S,8S)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7S,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                      (6S,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (6S,7S,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                      (8R,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8R,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8R,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8R,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8S,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8S,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8S,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (8S,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                      (R)-DRF053 + 0
                      1-(2-cyanoethyl)-6-(2-fluoro-4-methoxyphenyl)-3-methyl-4-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester 0
                      1-(meta-hydroxyphenyl)-4-hydroxy-3-isoquinolone 0
                      1-[(2,4-dichlorophenyl)methyl]-4-(methylthio)-2-oxo-6-phenyl-3-pyridinecarbonitrile 0
                      1-[(2,6-dichlorophenyl)methyl]-5-(4-methylphenyl)-2-oxo-3-pyridinecarbonitrile 0
                      1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea 0
                      1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea 0
                      1-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                      1-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                      1-[[4-(6-chloro-3-pyridinyl)phenyl]methyl]-5-(trifluoromethoxy)indole-2,3-dione 0
                      1-[[4-(6-fluoro-3-pyridinyl)phenyl]methyl]-5-(trifluoromethoxy)indole-2,3-dione 0
                      1-acetyl-4-(4-\{4-[(2-ethoxyphenyl)thio]-3-nitrophenyl\}pyridin-2-yl)piperazine 0
                      1-benzyl-3-butyl-4-hydroxy-6-phenylpyridin-2(1H)-one 0
                      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 372
                      13-(S)-hydroxy-N-(O-methyl)septoriamycin A 0
                      15-hydroxytenellin 0
                      17-acetoxy-N-(O-methyl)septoriamycin A 0
                      17-hydroxy-N-(O-methyl)septoriamycin A 0
                      2,4-difluoro-N-[2-methoxy-4-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide 0
                      2,6-dichlorobenzoic acid [3-cyano-6-(3-methoxyphenyl)-2-pyridinyl] ester 0
                      2,6-diphenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione 0
                      2-(3,4-dichlorophenoxy)-6-(4-fluorophenyl)-3-pyridinecarbonitrile 0
                      2-(4-chloro-2-methylphenoxy)-6-(4-fluorophenyl)-3-pyridinecarbonitrile 0
                      2-(dimethylamino)-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-(dimethylamino)-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                      2-Acetoxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine 2
                      2-[(3-cyano-4,6-diphenyl-2-pyridinyl)thio]-3-methylbutanoic acid 0
                      2-[(3-cyano-4-phenyl-6-thiophen-2-yl-2-pyridinyl)thio]-N-propan-2-ylacetamide 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                      2-[2,4-bis(4-ethoxyphenyl)-6-methyl-1-pyridin-1-iumyl]-N,N-diethylethanamine 0
                      2-[[2-(1-adamantyl)-2-oxoethyl]thio]-6-amino-4-(4-chlorophenyl)pyridine-3,5-dicarbonitrile 0
                      2-[[3-cyano-4-(2-methoxyphenyl)-6-phenyl-2-pyridinyl]thio]acetic acid 0
                      2-[[3-cyano-6-(3,4-dimethoxyphenyl)-2-pyridinyl]thio]-N-(2-furanylmethyl)acetamide 0
                      2-[[3-cyano-6-(4-methoxyphenyl)-4-phenyl-2-pyridinyl]thio]-N-(5-methyl-2-thiazolyl)acetamide 0
                      2-[[3-cyano-6-(4-methylphenyl)-4-(trifluoromethyl)-2-pyridinyl]thio]-N-(4-methoxyphenyl)acetamide 0
                      2-amino-1-(2-methylphenyl)-4-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                      2-amino-1-(4-chlorophenyl)-4-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                      2-amino-1-(4-methylphenyl)-6-oxo-4-phenylpyridine-3,5-dicarbonitrile 0
                      2-amino-1-methyl-6-oxo-4-phenylpyridine-3,5-dicarbonitrile 0
                      2-amino-4-(2-chlorophenyl)-6-(ethylthio)pyridine-3,5-dicarbonitrile 0
                      2-amino-4-(2-chlorophenyl)-6-[(4-chlorophenyl)thio]pyridine-3,5-dicarbonitrile 0
                      2-amino-4-(4-chlorophenyl)-1-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                      2-amino-4-(4-chlorophenyl)-6-methyl-3-pyridinecarbonitrile 0
                      2-amino-4-phenyl-6-(1-pyrrolidinyl)pyridine-3,5-dicarbonitrile 0
                      2-chloro-5-methyl-1-oxo-3-phenyl-4-pyrido[1,2-a]benzimidazolecarbonitrile 0
                      2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid 3
                      2-cyclopropyl-1-[(3R)-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]ethanone 0
                      2-cyclopropyl-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-cyclopropyl-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                      2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      2-fluoro-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-fluoro-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                      2-methoxy-4-(1-methyl-4-pyridin-1-iumyl)phenol 0
                      2-methylsulfonyl-4,6-diphenyl-3-thieno[2,3-b]pyridinamine 0
                      2-oxo-6-phenyl-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile 0
                      3',4'-anti-prepyridomacrolidin A 0
                      3',4'-syn-prepyridomacrolidin A 0
                      3',4'-syn-prepyridomacrolidin B 0
                      3,5-Pyridinedicarboxylic acid, 2-(hydroxymethyl)-6-methyl-4-(2-nitrophenyl)-, 5-methyl ester 0
                      3-(1,3-benzodioxol-5-yl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                      3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                      3-(4-fluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                      3-(6-Methylpyridin-2-yl)-2-(4-pyridin-3-ylphenyl)-1,3-thiazolidin-4-one 0
                      3-Pyrid-4-ylbenzoic acid 0
                      3-Pyridin-4-ylaniline 0
                      3-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2R,3R,5S,6R)-6-[(2R)-butan-2-yl]-3,5-dimethyloxan-2-yl]-1,4-dihydroxy-5-phenylpyridin-2-one 0
                      3-[(2R,3R,5S,6R)-6-[(2R)-butan-2-yl]-3,5-dimethyloxan-2-yl]-4-hydroxy-1-methoxy-5-phenylpyridin-2-one 0
                      3-[(2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                      3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      3-[2-methoxy-6-(4-methoxyphenyl)-3-pyridinyl]-5-(methoxymethyl)-1,2,4-oxadiazole 0
                      3-[2-methoxy-6-(4-methylphenyl)-3-pyridinyl]-5-(3-pyridinyl)-1,2,4-oxadiazole 0
                      3-[4-(5-pentyl-2-pyridinyl)phenyl]-2-propenamide 0
                      3-amino-4-(4-chlorophenyl)-6-cyclopropyl-2-thieno[2,3-b]pyridinecarbonitrile 0
                      3-amino-6-cyclopropyl-4-(4-methoxyphenyl)-2-thieno[2,3-b]pyridinecarbonitrile 0
                      3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                      3-cyclohexyl-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                      3-cyclopentyl-1-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-1-methylurea 0
                      3-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      3-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      4-(3,4-dimethoxyphenyl)pyridine 0
                      4-(5-propyl-2-pyridyl)benzonitrile 0
                      4-Phenylpyridine 0
                      4-Pyrid-3-ylbenzoic acid 0
                      4-Pyridin-3-ylaniline 0
                      4-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      4-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      4-[(2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      4-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      4-[(2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                      4-[2-[2,4-bis(4-ethoxyphenyl)-6-methyl-1-pyridin-1-iumyl]ethyl]morpholine 0
                      4-[[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                      4-[[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                      4-[[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                      4-[[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                      4-[[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                      4-[[2-[4-(2-chlorophenyl)-2-oxo-6,7-dihydro-5H-cyclopenta[b]pyridin-1-yl]-1-oxoethyl]amino]-1-piperidinecarboxylic acid ethyl ester 0
                      4-[[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-[[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                      4-chlorobenzoic acid [3-cyano-6-(3-methoxyphenyl)-2-pyridinyl] ester 0
                      4-cyano-N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide 0
                      4-hydroxy-3-[(2R,3R,5S,6S)-6-[(2R)-4-hydroxybutan-2-yl]-3,5-dimethyloxan-2-yl]-1-methoxy-5-phenylpyridin-2-one 0
                      4-hydroxy-6,7-diphenyl-5,6-dihydro-2H-pyrano[3,2-c]pyridine-2,5-dione 0
                      4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one 0
                      5-(2-furanyl)-3-[2-methoxy-6-(4-methylphenyl)-3-pyridinyl]-1,2,4-oxadiazole 0
                      5-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-7-thiazolo[4,5-b]pyridinecarboxylic acid 0
                      5-(4-methylphenyl)-2-(1-piperidinyl)-7-thiazolo[4,5-b]pyridinecarboxylic acid 0
                      5-Phenyl-2-pyridinamine 0
                      5-cyano-6-phenoxy-2-phenyl-3-pyridinecarboxylic acid ethyl ester 0
                      6-(3-bromophenyl)-2-methyl-3-pyridinecarboxylic acid 0
                      6-(4-Fluorophenyl)-4-phenyl-3-cyanopyridine-2(1H)-thione 0
                      6-(4-bromophenyl)-2-methyl-3-pyridinecarboxylic acid 0
                      6-(4-bromophenyl)-3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4-(trifluoromethyl)pyrazolo[3,4-b]pyridine 0
                      6-(4-chlorophenyl)-2-methyl-3-pyridinecarboxylic acid methyl ester 0
                      6-(4-chlorophenyl)-3-cyano-2-oxo-1H-pyridine-4-carboxylic acid ethyl ester 0
                      6-(4-chlorophenyl)-4-(methylthio)-2-oxo-1H-pyridine-3-carbonitrile 0
                      6-(4-fluorophenyl)-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile 0
                      6-(4-heptoxyphenyl)-3-pyridinecarbonitrile 0
                      6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide 0
                      6-Phenylpyrid-3-ylamine 0
                      6-[4,6-bis(4-methoxyphenyl)-2-pyridinyl]-4H-1,4-benzoxazin-3-one 0
                      6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide 0
                      6-amino-4-(4-fluorophenyl)-3-methyl-1-phenyl-5-pyrazolo[3,4-b]pyridinecarbonitrile 0
                      6-amino-4-(4-tert-butylphenyl)-3-methyl-1-phenyl-5-pyrazolo[3,4-b]pyridinecarbonitrile 0
                      6-methyl-5-phenyl-2-(phenylthio)-3-pyridinecarbonitrile 0
                      7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid 0
                      8-methoxy-1-(4-methoxyphenyl)-3-methyl-2-oxidobenzofuro[3,2-c]pyridin-2-ium 0
                      Acremolactone B 0
                      Alternaphenol C 0
                      Anti-13,15-dihydroxypretenellin B 0
                      Babetaianin 0
                      CJ-15,696 0
                      CJ-16,169 0
                      CJ-16,170 0
                      CJ-16,171 0
                      CJ-16,173 0
                      CJ-16,174 0
                      CJ-16,196 0
                      CJ-16,197 0
                      CP-471,326 0
                      CP-473,195 0
                      CP-473,198 0
                      Campyridone A 0
                      Campyridone B 0
                      Citridone A 0
                      Citridone B 0
                      Citridone B' 0
                      Citridone D 0
                      Citridone E 0
                      Citridone F 0
                      Citridone G 0
                      Citridone H 0
                      Citridone I 0
                      Citridone J 0
                      Citridone K 0
                      Citridone L 0
                      Coprismycin A 0
                      Coprismycin B 0
                      Dehydrofelodipine 0
                      Didymellamide B 0
                      Farinosone A 0
                      Farinosone B 0
                      Fluridone 2
                      HR 780 0
                      Hydroxyl-ilicicolin H 0
                      Ilicicolin I 0
                      LSM-10124 0
                      LSM-10135 0
                      LSM-10142 0
                      LSM-10308 0
                      LSM-10321 0
                      LSM-10353 0
                      LSM-10370 0
                      LSM-10401 0
                      LSM-10428 0
                      LSM-10435 0
                      LSM-10486 0
                      LSM-10651 0
                      LSM-10678 0
                      LSM-10855 0
                      LSM-10894 0
                      LSM-10927 0
                      LSM-10936 0
                      LSM-10938 0
                      LSM-10939 0
                      LSM-10948 0
                      LSM-11029 0
                      LSM-11161 0
                      LSM-11233 0
                      LSM-11419 0
                      LSM-11430 0
                      LSM-11445 0
                      LSM-11448 0
                      LSM-11587 0
                      LSM-11608 0
                      LSM-11626 0
                      LSM-11648 0
                      LSM-11727 0
                      LSM-11739 0
                      LSM-11893 0
                      LSM-12017 0
                      LSM-12034 0
                      LSM-12046 0
                      LSM-12058 0
                      LSM-12107 0
                      LSM-12267 0
                      LSM-12344 0
                      LSM-12352 0
                      LSM-12400 0
                      LSM-12443 0
                      LSM-12503 0
                      LSM-12630 0
                      LSM-12730 0
                      LSM-12768 0
                      LSM-12789 0
                      LSM-12796 0
                      LSM-12888 0
                      LSM-12904 0
                      LSM-12933 0
                      LSM-13009 0
                      LSM-13309 0
                      LSM-13336 0
                      LSM-13402 0
                      LSM-13448 0
                      LSM-13673 0
                      LSM-13677 0
                      LSM-13703 0
                      LSM-13738 0
                      LSM-13745 0
                      LSM-13850 0
                      LSM-13903 0
                      LSM-13904 0
                      LSM-14097 0
                      LSM-14156 0
                      LSM-14175 0
                      LSM-14186 0
                      LSM-14328 0
                      LSM-14389 0
                      LSM-14560 0
                      LSM-14988 0
                      LSM-19696 0
                      LSM-20825 0
                      LSM-20909 0
                      LSM-26276 0
                      LSM-26409 0
                      LSM-28526 0
                      LSM-37078 0
                      LSM-37097 0
                      LSM-37112 0
                      LSM-42140 0
                      LSM-8457 0
                      LSM-8465 0
                      LSM-8483 0
                      LSM-8528 0
                      LSM-8613 0
                      LSM-8616 0
                      LSM-8651 0
                      LSM-8677 0
                      LSM-8692 0
                      LSM-8762 0
                      LSM-8776 0
                      LSM-8800 0
                      LSM-8823 0
                      LSM-9034 0
                      LSM-9036 0
                      LSM-9066 0
                      LSM-9098 0
                      LSM-9144 0
                      LSM-9267 0
                      LSM-9292 0
                      LSM-9295 0
                      LSM-9352 0
                      LSM-9355 0
                      LSM-9366 0
                      LSM-9610 0
                      LSM-9618 0
                      LSM-9632 0
                      LSM-9674 0
                      LSM-9686 0
                      LSM-9719 0
                      LSM-9720 0
                      LSM-9817 0
                      LSM-9818 0
                      LSM-9930 0
                      Lucidimine E 0
                      Militarinone D 0
                      N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide 0
                      N-Sulfonyloxy-PhIP 0
                      N-[(1S)-3-methyl-1-(\{(4S)-3-oxo-1-[(3-pyridin-2-ylphenyl)acetyl]azepan-4-yl\}carbamoyl)butyl]-5-(2-morpholin-4-ylethoxy)-1-benzofuran-2-carboxamide 0
                      N-[2-(3-chlorophenyl)ethyl]-2-[[3-cyano-6-(3-methoxyphenyl)-2-pyridinyl]thio]acetamide 0
                      N-[3,5-dicyano-1-(4-methylphenyl)-6-oxo-4-phenyl-2-pyridinyl]acetamide 0
                      N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3R)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2R,3R)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-methoxy-N-methylbenzenesulfonamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2R,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2R,3S)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                      N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-(2-methoxyethyl)acetamide 0
                      N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-propylacetamide 0
                      N-[[(2R,3S,4S)-1-[cyclopropyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-methylacetamide 0
                      N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                      N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                      N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3R)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2S,3R)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2S,3R,4R)-1-[cyclopropyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-methylacetamide 0
                      N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                      N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                      N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-propylacetamide 0
                      N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                      N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                      N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                      N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                      N-[[(2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                      N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                      N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                      N-[[(2S,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2S,3S)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                      N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                      N-methyl-N-(3-pyridin-4-ylbenzyl)amine 0
                      Orbiocrellin B 0
                      Pretenellin B 0
                      Prototenellin F 0
                      Pyridinitril 0
                      Pyridomacrolidin 0
                      Pyridovericin 0
                      Sinensine 0
                      TMC-69 0
                      Tenellin 0
                      Tersone G 0
                      Tolypyridone C 0
                      Torrubiellone C 0
                      Vancouverone A 0
                      [(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                      [(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                      [(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-[4-(phenylmethyl)-1-piperazinyl]methanone 0
                      [(3R)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(3R)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(3R)-3-[(2S,3S,5R,6R)-6-(4-hydroxy-1-methoxy-2-oxo-5-phenylpyridin-3-yl)-3,5-dimethyloxan-2-yl]butyl] acetate 0
                      [(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                      [(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                      [(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(3S)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                      [(8R,9R,10R)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9R,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9R,10S)-6-(cyclopropylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9R,10S)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9S,10R)-6-(2-methylphenyl)sulfonyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9S,10R)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8R,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9R,10R)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10R)-6-(cyclopropylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10R)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10R)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10S)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [(8S,9S,10S)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                      [5-[2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]-4-morpholin-4-ylpyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol 0
                      \{4-[5-(Trifluoromethyl)pyrid-2-yl]phenyl\}methylamine 0
                      dehydronifedipine 0
                      delanzomib 0
                      ethyl 3-cyano-2-hydroxy-6-phenylisonicotinate 0
                      fiboflapon 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19918
    subatomic particle 19916
      composite particle 19916
        hadron 19916
          baryon 19916
            nucleon 19916
              atomic nucleus 19916
                atom 19916
                  main group element atom 19866
                    p-block element atom 19866
                      carbon group element atom 19811
                        carbon atom 19806
                          organic molecular entity 19806
                            organic molecule 19758
                              organic cyclic compound 19565
                                organic heterocyclic compound 18906
                                  organic heteromonocyclic compound 17826
                                    pyridines 11526
                                      phenylpyridine 377
                                        (+)-didymellamide B 0
                                        (+)-ganoapplanatumine A 0
                                        (+)-tersone A 0
                                        (+)-tersone B 0
                                        (+)-tersone C 0
                                        (+)-tersone D 0
                                        (+)-tersone E 0
                                        (+/-)-didymellamide E 0
                                        (-)-ganoapplanatumine A 0
                                        (-)-tersone A 0
                                        (-)-tersone B 0
                                        (-)-tersone C 0
                                        (-)-tersone D 0
                                        (-)-tersone E 0
                                        (10,11-Z)-syn-13-hydroxypretenellin B 0
                                        (2R)-2-[(4R,5R)-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-2-yl]-1-propanol 0
                                        (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(2-fluorophenyl)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3R,3aS,9bS)-1-(cyclopentanecarbonyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                        (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-7-(3-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-acetyl-N-[3-(dimethylamino)propyl]-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-1-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-N-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-1-ethyl-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-2-N-cyclobutyl-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                        (2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methyl-2-(piperidine-1-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(1,3-thiazol-2-yl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-1-methyl-6-oxo-N-[2-(1-piperidinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-2-(morpholine-4-carbonyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-2-(4-methylpiperazine-1-carbonyl)-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                        (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-[oxo(1-piperidinyl)methyl]-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-[4-(dimethylcarbamoyl)phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-N-(2-phenylethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N,1-diethyl-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-(4-oxanylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-7-[3-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-cyclobutyl-1-[2-(dimethylamino)acetyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-cyclobutyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2R,3R,3aS,9bS)-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                        (2R,3R,4S)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-1-azetidinecarboxamide 0
                                        (2R,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (2R,3S)-2-[(dimethylamino)methyl]-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2R,3S,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-(4-pyridin-3-ylphenyl)azetidine-1-carboxamide 0
                                        (2R,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (2S)-2-[(4S,5S)-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-2-yl]-1-propanol 0
                                        (2S)-2-[[9-propan-2-yl-6-[[4-(2-pyridinyl)phenyl]methylamino]-2-purinyl]amino]-1-butanol 0
                                        (2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3R,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-1-azetidinecarboxamide 0
                                        (2S,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-8-(2-methylphenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(propyl)amino]methyl]-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(2-fluorophenyl)-2-[[(3-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(2-pyridinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(4-oxanylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one 0
                                        (2S,3S,3aR,9bR)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-(cyclopropanecarbonyl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-(4-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                        (2S,3S,3aR,9bR)-1-[cyclopentyl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-acetyl-N-[3-(dimethylamino)propyl]-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-ethyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-1-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-N-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-1-ethyl-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-7-(2-fluorophenyl)-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methyl-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propyl-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-1-methyl-6-oxo-N-(2-piperidin-1-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-2-[4-morpholinyl(oxo)methyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                        (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                        (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-(piperidine-1-carbonyl)-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-N-(2-phenylethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N,1-diethyl-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-7-(3-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-7-(3-fluorophenyl)-3-(hydroxymethyl)-1-(4-oxanylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-7-[3-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-cyclobutyl-1-[2-(dimethylamino)acetyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-cyclobutyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-cyclohexyl-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N-ethyl-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                        (2S,3S,3aR,9bR)-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(4-methoxyphenyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                        (2S,3S,3aR,9bR)-N2-cyclobutyl-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-N1-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                        (2S,3S,4R)-2-cyano-N-(4-fluorophenyl)-4-(hydroxymethyl)-3-(4-pyridin-3-ylphenyl)azetidine-1-carboxamide 0
                                        (2S,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3-methoxyphenyl)methyl]-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-[(R)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-ethylsulfonyl-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                                        (3R)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                                        (3R)-4-(3-bromophenyl)-2-[(R)-tert-butylsulfinyl]-N-cyclohexyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                                        (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-N-(1,3-benzodioxol-5-ylmethyl)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3R)-N6-(2,3-dihydro-1H-inden-2-yl)-3-(2-hydroxyethyl)-N2-propan-2-yl-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2,6-dicarboxamide 0
                                        (3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-3-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(2-pyridin-4-ylethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3-methoxyphenyl)methyl]-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-N-ethyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-[(S)-tert-butylsulfinyl]-N-[(2-fluorophenyl)methyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-ethylsulfonyl-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                                        (3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-2-tert-butylsulfinyl-4-[3-[2-(3,4-dimethoxyphenyl)ethynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                                        (3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid 0
                                        (3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-N-[3-(4-morpholinyl)propyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-4-(3-bromophenyl)-2-[(S)-tert-butylsulfinyl]-N-cyclohexyl-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester 0
                                        (3S)-4-[3-(1-cyclohexenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-2-methylsulfonyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-N-(1,3-benzodioxol-5-ylmethyl)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide 0
                                        (3S)-N6-(2,3-dihydro-1H-inden-2-yl)-3-(2-hydroxyethyl)-N2-propan-2-yl-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2,6-dicarboxamide 0
                                        (4-Pyrid-4-ylphenyl)methanol 0
                                        (6R,7R,8R)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7R,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6R,7R,8S)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7R,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6R,7S,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6R,7S,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6R,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6S,7R,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6S,7R,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7S,8R)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7S,8R)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6S,7S,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6S,7S,8S)-8-(hydroxymethyl)-4-(2-methoxy-1-oxoethyl)-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7S,8S)-8-(hydroxymethyl)-4-[4-oxanyl(oxo)methyl]-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one 0
                                        (6S,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (6S,7S,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide 0
                                        (8R,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8R,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8R,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8R,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8S,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8S,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8S,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (8S,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide 0
                                        (R)-DRF053 + 0
                                        1-(2-cyanoethyl)-6-(2-fluoro-4-methoxyphenyl)-3-methyl-4-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester 0
                                        1-(meta-hydroxyphenyl)-4-hydroxy-3-isoquinolone 0
                                        1-[(2,4-dichlorophenyl)methyl]-4-(methylthio)-2-oxo-6-phenyl-3-pyridinecarbonitrile 0
                                        1-[(2,6-dichlorophenyl)methyl]-5-(4-methylphenyl)-2-oxo-3-pyridinecarbonitrile 0
                                        1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea 0
                                        1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea 0
                                        1-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea 0
                                        1-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea 0
                                        1-[[4-(6-chloro-3-pyridinyl)phenyl]methyl]-5-(trifluoromethoxy)indole-2,3-dione 0
                                        1-[[4-(6-fluoro-3-pyridinyl)phenyl]methyl]-5-(trifluoromethoxy)indole-2,3-dione 0
                                        1-acetyl-4-(4-\{4-[(2-ethoxyphenyl)thio]-3-nitrophenyl\}pyridin-2-yl)piperazine 0
                                        1-benzyl-3-butyl-4-hydroxy-6-phenylpyridin-2(1H)-one 0
                                        1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 372
                                        13-(S)-hydroxy-N-(O-methyl)septoriamycin A 0
                                        15-hydroxytenellin 0
                                        17-acetoxy-N-(O-methyl)septoriamycin A 0
                                        17-hydroxy-N-(O-methyl)septoriamycin A 0
                                        2,4-difluoro-N-[2-methoxy-4-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide 0
                                        2,6-dichlorobenzoic acid [3-cyano-6-(3-methoxyphenyl)-2-pyridinyl] ester 0
                                        2,6-diphenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione 0
                                        2-(3,4-dichlorophenoxy)-6-(4-fluorophenyl)-3-pyridinecarbonitrile 0
                                        2-(4-chloro-2-methylphenoxy)-6-(4-fluorophenyl)-3-pyridinecarbonitrile 0
                                        2-(dimethylamino)-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-(dimethylamino)-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylacetamide 0
                                        2-Acetoxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine 2
                                        2-[(3-cyano-4,6-diphenyl-2-pyridinyl)thio]-3-methylbutanoic acid 0
                                        2-[(3-cyano-4-phenyl-6-thiophen-2-yl-2-pyridinyl)thio]-N-propan-2-ylacetamide 0
                                        2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-morpholin-4-ylethanone 0
                                        2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone 0
                                        2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[(3-pyridin-4-ylphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                        2-[2,4-bis(4-ethoxyphenyl)-6-methyl-1-pyridin-1-iumyl]-N,N-diethylethanamine 0
                                        2-[[2-(1-adamantyl)-2-oxoethyl]thio]-6-amino-4-(4-chlorophenyl)pyridine-3,5-dicarbonitrile 0
                                        2-[[3-cyano-4-(2-methoxyphenyl)-6-phenyl-2-pyridinyl]thio]acetic acid 0
                                        2-[[3-cyano-6-(3,4-dimethoxyphenyl)-2-pyridinyl]thio]-N-(2-furanylmethyl)acetamide 0
                                        2-[[3-cyano-6-(4-methoxyphenyl)-4-phenyl-2-pyridinyl]thio]-N-(5-methyl-2-thiazolyl)acetamide 0
                                        2-[[3-cyano-6-(4-methylphenyl)-4-(trifluoromethyl)-2-pyridinyl]thio]-N-(4-methoxyphenyl)acetamide 0
                                        2-amino-1-(2-methylphenyl)-4-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                                        2-amino-1-(4-chlorophenyl)-4-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                                        2-amino-1-(4-methylphenyl)-6-oxo-4-phenylpyridine-3,5-dicarbonitrile 0
                                        2-amino-1-methyl-6-oxo-4-phenylpyridine-3,5-dicarbonitrile 0
                                        2-amino-4-(2-chlorophenyl)-6-(ethylthio)pyridine-3,5-dicarbonitrile 0
                                        2-amino-4-(2-chlorophenyl)-6-[(4-chlorophenyl)thio]pyridine-3,5-dicarbonitrile 0
                                        2-amino-4-(4-chlorophenyl)-1-(4-methylphenyl)-6-oxopyridine-3,5-dicarbonitrile 0
                                        2-amino-4-(4-chlorophenyl)-6-methyl-3-pyridinecarbonitrile 0
                                        2-amino-4-phenyl-6-(1-pyrrolidinyl)pyridine-3,5-dicarbonitrile 0
                                        2-chloro-5-methyl-1-oxo-3-phenyl-4-pyrido[1,2-a]benzimidazolecarbonitrile 0
                                        2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid 3
                                        2-cyclopropyl-1-[(3R)-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]ethanone 0
                                        2-cyclopropyl-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-cyclopropyl-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(2-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide 0
                                        2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-phenyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        2-fluoro-N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-fluoro-N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-pyridin-4-yl-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzenesulfonamide 0
                                        2-methoxy-4-(1-methyl-4-pyridin-1-iumyl)phenol 0
                                        2-methylsulfonyl-4,6-diphenyl-3-thieno[2,3-b]pyridinamine 0
                                        2-oxo-6-phenyl-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile 0
                                        3',4'-anti-prepyridomacrolidin A 0
                                        3',4'-syn-prepyridomacrolidin A 0
                                        3',4'-syn-prepyridomacrolidin B 0
                                        3,5-Pyridinedicarboxylic acid, 2-(hydroxymethyl)-6-methyl-4-(2-nitrophenyl)-, 5-methyl ester 0
                                        3-(1,3-benzodioxol-5-yl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                                        3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-[[4-(2-pyridinyl)phenyl]methyl]amino]butyl]urea 0
                                        3-(4-fluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                                        3-(6-Methylpyridin-2-yl)-2-(4-pyridin-3-ylphenyl)-1,3-thiazolidin-4-one 0
                                        3-Pyrid-4-ylbenzoic acid 0
                                        3-Pyridin-4-ylaniline 0
                                        3-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2R,3R,5S,6R)-6-[(2R)-butan-2-yl]-3,5-dimethyloxan-2-yl]-1,4-dihydroxy-5-phenylpyridin-2-one 0
                                        3-[(2R,3R,5S,6R)-6-[(2R)-butan-2-yl]-3,5-dimethyloxan-2-yl]-4-hydroxy-1-methoxy-5-phenylpyridin-2-one 0
                                        3-[(2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2S,3R)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]-N,N-dimethylbenzamide 0
                                        3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(3-pyridinylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        3-[2-methoxy-6-(4-methoxyphenyl)-3-pyridinyl]-5-(methoxymethyl)-1,2,4-oxadiazole 0
                                        3-[2-methoxy-6-(4-methylphenyl)-3-pyridinyl]-5-(3-pyridinyl)-1,2,4-oxadiazole 0
                                        3-[4-(5-pentyl-2-pyridinyl)phenyl]-2-propenamide 0
                                        3-amino-4-(4-chlorophenyl)-6-cyclopropyl-2-thieno[2,3-b]pyridinecarbonitrile 0
                                        3-amino-6-cyclopropyl-4-(4-methoxyphenyl)-2-thieno[2,3-b]pyridinecarbonitrile 0
                                        3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                                        3-cyclohexyl-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea 0
                                        3-cyclopentyl-1-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-1-methylurea 0
                                        3-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        3-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        4-(3,4-dimethoxyphenyl)pyridine 0
                                        4-(5-propyl-2-pyridyl)benzonitrile 0
                                        4-Phenylpyridine 0
                                        4-Pyrid-3-ylbenzoic acid 0
                                        4-Pyridin-3-ylaniline 0
                                        4-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        4-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        4-[(2R,3R)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        4-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        4-[(2S,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-8-yl]benzonitrile 0
                                        4-[2-[2,4-bis(4-ethoxyphenyl)-6-methyl-1-pyridin-1-iumyl]ethyl]morpholine 0
                                        4-[[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                                        4-[[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                                        4-[[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                                        4-[[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                                        4-[[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-4-yl]methyl]benzoic acid methyl ester 0
                                        4-[[2-[4-(2-chlorophenyl)-2-oxo-6,7-dihydro-5H-cyclopenta[b]pyridin-1-yl]-1-oxoethyl]amino]-1-piperidinecarboxylic acid ethyl ester 0
                                        4-[[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-[[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl-methylamino]methyl]benzoic acid 0
                                        4-chlorobenzoic acid [3-cyano-6-(3-methoxyphenyl)-2-pyridinyl] ester 0
                                        4-cyano-N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide 0
                                        4-hydroxy-3-[(2R,3R,5S,6S)-6-[(2R)-4-hydroxybutan-2-yl]-3,5-dimethyloxan-2-yl]-1-methoxy-5-phenylpyridin-2-one 0
                                        4-hydroxy-6,7-diphenyl-5,6-dihydro-2H-pyrano[3,2-c]pyridine-2,5-dione 0
                                        4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one 0
                                        5-(2-furanyl)-3-[2-methoxy-6-(4-methylphenyl)-3-pyridinyl]-1,2,4-oxadiazole 0
                                        5-(3,4-dimethoxyphenyl)-2-(1-piperidinyl)-7-thiazolo[4,5-b]pyridinecarboxylic acid 0
                                        5-(4-methylphenyl)-2-(1-piperidinyl)-7-thiazolo[4,5-b]pyridinecarboxylic acid 0
                                        5-Phenyl-2-pyridinamine 0
                                        5-cyano-6-phenoxy-2-phenyl-3-pyridinecarboxylic acid ethyl ester 0
                                        6-(3-bromophenyl)-2-methyl-3-pyridinecarboxylic acid 0
                                        6-(4-Fluorophenyl)-4-phenyl-3-cyanopyridine-2(1H)-thione 0
                                        6-(4-bromophenyl)-2-methyl-3-pyridinecarboxylic acid 0
                                        6-(4-bromophenyl)-3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4-(trifluoromethyl)pyrazolo[3,4-b]pyridine 0
                                        6-(4-chlorophenyl)-2-methyl-3-pyridinecarboxylic acid methyl ester 0
                                        6-(4-chlorophenyl)-3-cyano-2-oxo-1H-pyridine-4-carboxylic acid ethyl ester 0
                                        6-(4-chlorophenyl)-4-(methylthio)-2-oxo-1H-pyridine-3-carbonitrile 0
                                        6-(4-fluorophenyl)-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile 0
                                        6-(4-heptoxyphenyl)-3-pyridinecarbonitrile 0
                                        6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide 0
                                        6-Phenylpyrid-3-ylamine 0
                                        6-[4,6-bis(4-methoxyphenyl)-2-pyridinyl]-4H-1,4-benzoxazin-3-one 0
                                        6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide 0
                                        6-amino-4-(4-fluorophenyl)-3-methyl-1-phenyl-5-pyrazolo[3,4-b]pyridinecarbonitrile 0
                                        6-amino-4-(4-tert-butylphenyl)-3-methyl-1-phenyl-5-pyrazolo[3,4-b]pyridinecarbonitrile 0
                                        6-methyl-5-phenyl-2-(phenylthio)-3-pyridinecarbonitrile 0
                                        7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid 0
                                        8-methoxy-1-(4-methoxyphenyl)-3-methyl-2-oxidobenzofuro[3,2-c]pyridin-2-ium 0
                                        Acremolactone B 0
                                        Alternaphenol C 0
                                        Anti-13,15-dihydroxypretenellin B 0
                                        Babetaianin 0
                                        CJ-15,696 0
                                        CJ-16,169 0
                                        CJ-16,170 0
                                        CJ-16,171 0
                                        CJ-16,173 0
                                        CJ-16,174 0
                                        CJ-16,196 0
                                        CJ-16,197 0
                                        CP-471,326 0
                                        CP-473,195 0
                                        CP-473,198 0
                                        Campyridone A 0
                                        Campyridone B 0
                                        Citridone A 0
                                        Citridone B 0
                                        Citridone B' 0
                                        Citridone D 0
                                        Citridone E 0
                                        Citridone F 0
                                        Citridone G 0
                                        Citridone H 0
                                        Citridone I 0
                                        Citridone J 0
                                        Citridone K 0
                                        Citridone L 0
                                        Coprismycin A 0
                                        Coprismycin B 0
                                        Dehydrofelodipine 0
                                        Didymellamide B 0
                                        Farinosone A 0
                                        Farinosone B 0
                                        Fluridone 2
                                        HR 780 0
                                        Hydroxyl-ilicicolin H 0
                                        Ilicicolin I 0
                                        LSM-10124 0
                                        LSM-10135 0
                                        LSM-10142 0
                                        LSM-10308 0
                                        LSM-10321 0
                                        LSM-10353 0
                                        LSM-10370 0
                                        LSM-10401 0
                                        LSM-10428 0
                                        LSM-10435 0
                                        LSM-10486 0
                                        LSM-10651 0
                                        LSM-10678 0
                                        LSM-10855 0
                                        LSM-10894 0
                                        LSM-10927 0
                                        LSM-10936 0
                                        LSM-10938 0
                                        LSM-10939 0
                                        LSM-10948 0
                                        LSM-11029 0
                                        LSM-11161 0
                                        LSM-11233 0
                                        LSM-11419 0
                                        LSM-11430 0
                                        LSM-11445 0
                                        LSM-11448 0
                                        LSM-11587 0
                                        LSM-11608 0
                                        LSM-11626 0
                                        LSM-11648 0
                                        LSM-11727 0
                                        LSM-11739 0
                                        LSM-11893 0
                                        LSM-12017 0
                                        LSM-12034 0
                                        LSM-12046 0
                                        LSM-12058 0
                                        LSM-12107 0
                                        LSM-12267 0
                                        LSM-12344 0
                                        LSM-12352 0
                                        LSM-12400 0
                                        LSM-12443 0
                                        LSM-12503 0
                                        LSM-12630 0
                                        LSM-12730 0
                                        LSM-12768 0
                                        LSM-12789 0
                                        LSM-12796 0
                                        LSM-12888 0
                                        LSM-12904 0
                                        LSM-12933 0
                                        LSM-13009 0
                                        LSM-13309 0
                                        LSM-13336 0
                                        LSM-13402 0
                                        LSM-13448 0
                                        LSM-13673 0
                                        LSM-13677 0
                                        LSM-13703 0
                                        LSM-13738 0
                                        LSM-13745 0
                                        LSM-13850 0
                                        LSM-13903 0
                                        LSM-13904 0
                                        LSM-14097 0
                                        LSM-14156 0
                                        LSM-14175 0
                                        LSM-14186 0
                                        LSM-14328 0
                                        LSM-14389 0
                                        LSM-14560 0
                                        LSM-14988 0
                                        LSM-19696 0
                                        LSM-20825 0
                                        LSM-20909 0
                                        LSM-26276 0
                                        LSM-26409 0
                                        LSM-28526 0
                                        LSM-37078 0
                                        LSM-37097 0
                                        LSM-37112 0
                                        LSM-42140 0
                                        LSM-8457 0
                                        LSM-8465 0
                                        LSM-8483 0
                                        LSM-8528 0
                                        LSM-8613 0
                                        LSM-8616 0
                                        LSM-8651 0
                                        LSM-8677 0
                                        LSM-8692 0
                                        LSM-8762 0
                                        LSM-8776 0
                                        LSM-8800 0
                                        LSM-8823 0
                                        LSM-9034 0
                                        LSM-9036 0
                                        LSM-9066 0
                                        LSM-9098 0
                                        LSM-9144 0
                                        LSM-9267 0
                                        LSM-9292 0
                                        LSM-9295 0
                                        LSM-9352 0
                                        LSM-9355 0
                                        LSM-9366 0
                                        LSM-9610 0
                                        LSM-9618 0
                                        LSM-9632 0
                                        LSM-9674 0
                                        LSM-9686 0
                                        LSM-9719 0
                                        LSM-9720 0
                                        LSM-9817 0
                                        LSM-9818 0
                                        LSM-9930 0
                                        Lucidimine E 0
                                        Militarinone D 0
                                        N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide 0
                                        N-Sulfonyloxy-PhIP 0
                                        N-[(1S)-3-methyl-1-(\{(4S)-3-oxo-1-[(3-pyridin-2-ylphenyl)acetyl]azepan-4-yl\}carbamoyl)butyl]-5-(2-morpholin-4-ylethoxy)-1-benzofuran-2-carboxamide 0
                                        N-[2-(3-chlorophenyl)ethyl]-2-[[3-cyano-6-(3-methoxyphenyl)-2-pyridinyl]thio]acetamide 0
                                        N-[3,5-dicyano-1-(4-methylphenyl)-6-oxo-4-phenyl-2-pyridinyl]acetamide 0
                                        N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2R,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3R)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2R,3R)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2R,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-methoxy-N-methylbenzenesulfonamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2R,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2R,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2R,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2R,3S)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2R,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                                        N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-(2-methoxyethyl)acetamide 0
                                        N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-propylacetamide 0
                                        N-[[(2R,3S,4S)-1-[cyclopropyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-methylacetamide 0
                                        N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                                        N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide 0
                                        N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3R)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3R)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2S,3R)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3R)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3R)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2S,3R)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2S,3R)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2S,3R,4R)-1-[cyclopropyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-methylacetamide 0
                                        N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                                        N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-ethylacetamide 0
                                        N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-propylacetamide 0
                                        N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylphenyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide 0
                                        N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide 0
                                        N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(4-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                        N-[[(2S,3S)-8-(3-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide 0
                                        N-[[(2S,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2S,3S)-8-(3-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclobutanecarboxamide 0
                                        N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide 0
                                        N-[[(2S,3S)-8-(4-cyanophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                        N-[[(2S,3S)-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2S,3S)-8-(4-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(2-pyridinyl)acetamide 0
                                        N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-[[(2S,3S)-8-[4-[dimethylamino(oxo)methyl]phenyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                        N-methyl-N-(3-pyridin-4-ylbenzyl)amine 0
                                        Orbiocrellin B 0
                                        Pretenellin B 0
                                        Prototenellin F 0
                                        Pyridinitril 0
                                        Pyridomacrolidin 0
                                        Pyridovericin 0
                                        Sinensine 0
                                        TMC-69 0
                                        Tenellin 0
                                        Tersone G 0
                                        Tolypyridone C 0
                                        Torrubiellone C 0
                                        Vancouverone A 0
                                        [(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                                        [(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                                        [(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-[4-(phenylmethyl)-1-piperazinyl]methanone 0
                                        [(3R)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(3R)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(3R)-3-[(2S,3S,5R,6R)-6-(4-hydroxy-1-methoxy-2-oxo-5-phenylpyridin-3-yl)-3,5-dimethyloxan-2-yl]butyl] acetate 0
                                        [(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                                        [(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-pyridinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone 0
                                        [(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(1-cyclopentenyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(3S)-2-tert-butylsulfinyl-4-[3-(3-cyclopentylprop-1-ynyl)phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-methyl-1-piperazinyl)methanone 0
                                        [(8R,9R,10R)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9R,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9R,10S)-6-(cyclopropylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9R,10S)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9S,10R)-6-(2-methylphenyl)sulfonyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9S,10R)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8R,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9R,10R)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10R)-6-(cyclopropylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10R)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10R)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10S)-6-(2-pyridinylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [(8S,9S,10S)-6-[(3-methoxyphenyl)methyl]-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 0
                                        [5-[2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]-4-morpholin-4-ylpyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol 0
                                        \{4-[5-(Trifluoromethyl)pyrid-2-yl]phenyl\}methylamine 0
                                        dehydronifedipine 0
                                        delanzomib 0
                                        ethyl 3-cyano-2-hydroxy-6-phenylisonicotinate 0
                                        fiboflapon 0
paths to the root